zacks.com · 10 jul

Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

benzinga.com · 9 jul

'Selling Winners, Buying Losers': Tech Stocks Drop as Energy Jumps to Start H2

A sharp rotation trade has taken over markets to start the second half of 2026, with investors dumping the year's biggest winners and piling into beaten-down names.

fool.com · 9 jul

Billionaire Steve Cohen Sold Amazon and Nvidia but Loaded Up on This Beaten-Down Stock

Amazon and Nvidia have been caught up in the AI trade, but have flatlined so far in 2026. Steve Cohen's Point72 Asset Management sold Amazon and Nvidia in the first quarter.

zacks.com · 6 jul

Boston Scientific (BSX) Stock Dips While Market Gains: Key Facts

Boston Scientific (BSX) closed at $44.6 in the latest trading session, marking a -1.2% move from the prior day.

seekingalpha.com · 6 jul

Boston Scientific: The Time Has Come To Catch This Falling Knife

Relative to its all-time high of $109.50 reached in September 2025, Boston Scientific Corporation's share price has declined by almost 60% to trade at around $45.00 per share. To put my money where my mouth is, I purchased my last shares on June 30th at an average price of $42.83. My overall purchase price now stands at $45.52. As part of its Q1-26 earnings, Boston Scientific announced a significant outlook revision, reducing its organic growth guidance for fiscal 2026 to a range between 6.5% and 8.0%.

zacks.com · 30 jun

Boston Scientific (BSX) Stock Drops Despite Market Gains: Important Facts to Note

In the most recent trading session, Boston Scientific (BSX) closed at $42.68, indicating a -1.84% shift from the previous trading day.

seekingalpha.com · 25 jun

Boston Scientific's Fall From Penthouse To Doghouse Creates A Value Opportunity

Boston Scientific has suffered a 50% share price decline amid decelerating growth and competitive threats, but fundamentals-based valuation now appears attractive. Growth in key segments like electrophysiology and Watchman has slowed due to increased competition, reimbursement cuts, and less impressive clinical trial data. Management now guides to sub-10% revenue growth (6.5%-8% for the year), but I still expect 7.5% annualized growth over five years and improving margins.

zacks.com · 24 jun

Boston Scientific (BSX) Registers a Bigger Fall Than the Market: Important Facts to Note

In the most recent trading session, Boston Scientific (BSX) closed at $44.46, indicating a -2.5% shift from the previous trading day.